Cardamonin inhibits the expression of P-glycoprotein and enhances the anti-proliferation of paclitaxel on SKOV3-Taxol cells

• Published in: Journal of natural medicines 2022, Vol.76 (1), p.220-233
• Main Authors: Ding, Qiuhua, Niu, Peiguang, Zhu, Yanting, Chen, Huajiao, Shi, Daohua
• Format: Article
• Language: English
• Subjects: Apoptosis; ATP Binding Cassette Transporter, Subfamily B - genetics; ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics; Biological products; Biomedical and Life Sciences; Biomedicine; Cell activation; Cell Line, Tumor; Cell proliferation; Chalcones - pharmacology; Complementary & Alternative Medicine; Cytotoxicity; Flowers & plants; Gene expression; Humans; MDR1 protein; Medicinal Chemistry; Molecular modelling; mRNA; NF-κB protein; Original Paper; Ovarian cancer; Ovarian Neoplasms; P-Glycoprotein; Paclitaxel; Paclitaxel - pharmacology; Pharmacology/Toxicology; Pharmacy; Plant Sciences; Tumor necrosis factor-α; Verapamil
• ISSN: 1340-3443; 1861-0293
• DOI: 10.1007/s11418-021-01583-1

Paclitaxel is widely used in the first-line treatment of ovarian cancer. Nevertheless, the development of acquired resistance to paclitaxel is a major obstacle for the therapy in clinic. Cardamonin is a novel anticancer chalcone which exhibits a wide range of pharmacological activities. However, the effect of cardamonin on paclitaxel-resistant ovarian cancer cells and its underlying molecular mechanisms are unknown. Here, we revealed whether cardamonin had a resensitivity for paclitaxel and furtherly explored the underlying mechanisms on SKOV3-Taxol cells. Our results showed that cardamonin combined with paclitaxel had a synergistic effect of anti-proliferation in SKOV3-Taxol cells, and CI was less than one. Cells apoptosis and G2/M phase arrest were enhanced by cardamonin with paclitaxel in a concentration-dependent way on SKOV3-Taxol cells ( P